NCT06730061进行中（未招募）3 期
A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Ipsen
- 入组人数
- 18
- 试验地点
- 16
- 主要终点
- Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULN
研究概览
简要总结
The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease.
PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis).
PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. In this study all participants will receive a daily dose of elafibranor (the study intervention).
The main aim of this study is to determine if elafibranor reduces alkaline phosphatase (ALP) and total bilirubin levels. High ALP and bilirubin levels in the blood can indicate liver disease.
There will be 4 periods in this study: A screening period (up to 10 weeks) to assess whether the participant can take part. A treatment period (52 weeks) where all eligible participants will receive elafibranor. A variable treatment extension period (2-5 years) from End Of Treatment (EOT) period up to the commercial availability of elafibranor in Japan. A follow-up period (4 weeks) where participants' health will be monitored.
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a non-invasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to approximately 6 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have provided written informed consent and agree to comply with the study protocol.
- •Japanese male or female participants aged 18 to 75 years inclusive at Screening Visit 1 (SV1).
- •PBC diagnosis as described in the study protocol
- •ALP ≥1.67×ULN (mean value based on samples collected at SV1 and SV2).
- •TB ≤2×ULN at SV1 and SV
- •Must have at least 4 available values for PBC Worst Itch Numeric Rating Scale (NRS) during each of the 7-day intervals in the 14 days prior to visit (V)1, for a total of at least 8 values for PBC Worst Itch NRS in the last 14 days prior to V
- •Participants taking UDCA for at least 12 months (stable dose ≥3 months) prior to screening, or unable to tolerate UDCA treatment (no UDCA for ≥3 months) prior to screening (per country standard-of-care dosing).
- •If on colchicine, must be on a stable dose for ≥3 months prior to screening.
- •Medications for management of pruritus (for example, cholestyramine, rifampicin, naltrexone, sertraline or nalfurafine hydrochloride) must be on a stable dose for ≥3 months prior to screening.
- •Participants taking statins or ezetimibe must be on a stable dose for ≥2 months prior to screening.
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
排除标准
- •* History or presence of other concomitant liver disease
- •* Participants with known cirrhosis who have a Child-Pugh B or C classification.
- •* Participants with cirrhosis with Child-Pugh A classification are allowed.
- •* History or presence of clinically significant hepatic decompensation,
- •* Medical conditions that may cause non-hepatic increases in ALP (for example, Paget's disease) or which may diminish life expectancy to \<2 years, including known cancers.
- •* Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.
- •* Participant has a positive test for human immunodeficiency virus (HIV) Type 1 or 2 at screening, or participant is known to have tested positive for HIV.
- •* Evidence of any other unstable or untreated clinically significant immunological, endocrine, haematologic, gastrointestinal, neurological, or psychiatric disease as evaluated by the investigator; other clinically significant medical conditions that are not well controlled.
- •* History of alcohol abuse, defined as consumption of more than 30 g pure alcohol per day for men, and more than 20 g pure alcohol per day for women, or other substance abuse within 1 year prior to SV1.
- •* For female participants: known pregnancy, or has a positive serum pregnancy test, or breastfeeding.
- •* Administration of the following medications are prohibited as specified below:
- •1. 1 month prior to screening: fibrates.
- •2. 2 months prior to screening: glitazones.
- •3. For participants with previous exposure to obeticholic acid (OCA), OCA should be discontinued 3 months prior to screening.
- •4. 3 months prior to screening: azathioprine, cyclosporine (systemic), methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (parenteral and oral chronic administration only); potentially hepatotoxic drugs (including α-methyldopa, sodium valproate/valproic acid isoniazid, or nitrofurantoin).
- •5. 12 months prior to screening: antibodies or immunotherapy directed against interleukins (ILs) or other cytokines or chemokines.
- •* Participants who are currently participating in, plan to participate in, or have participated in an investigational drug study or medical device study containing active substance within 30 days or 5 half-lives, whichever is longer, prior to screening; for participants with previous exposure to seladelpar, seladelpar should be discontinued 3 months prior to screening.
- •* Participants with previous exposure to elafibranor.
- •* SV1 or SV2 value ALT and/or AST \>5×ULN.
- •* For participants with aminotransferases or TB \>ULN at SV1, variability (between SV1 and SV2) of aminotransferases or TB \>40%.
- •* SV1 value albumin \<3.0 g/dL.
- •* Severely advanced participants according to Rotterdam criteria (TB \>ULN and albumin \1.3 due to altered hepatic function.
- •* SV1 creatine phosphokinase (CPK) \>2×ULN.
- •* SV1 serum creatinine \>1.5 mg/dL.
- •* Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as participants with markers of kidney failure damage or estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2) calculated by modification of diet in renal disease study (MDRD).
- •* SV1 platelet count \<150×103/μL.
- •* Alpha-fetoprotein (AFP) \>20 ng/mL with 4-phase liver computerised tomography (CT) or magnetic resonance imaging (MRI) imaging suggesting presence of liver cancer.
- •* Known hypersensitivity to the investigational product or to any of the formulation excipients of the elafibranor tablet.
- •* Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
研究组 & 干预措施
Elafibranor
Experimental
Participants will take the study intervention by mouth (swallow whole) once daily
干预措施: Elafibranor (Drug)
结局指标
主要结局
Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULN
时间窗: At Week 52
次要结局
- Percentage of participants with TB ≤0.6×ULN(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of Participants who normalised ALP Levels(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in ALP Levels(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of Participants With ALP Level response(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP <1.5×ULN, ALP decrease ≥40% and TB ≤ULN.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP <3×ULN, aspartate aminotransferase (AST) <2×ULN and Total Bilirubin (TB) <1 mg/dL (Paris I criteria).(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP ≤1.5×ULN, AST ≤1.5×ULN and TB ≤ULN (Paris II criteria).(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with TB response rate of 15% change.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with normalisation of abnormal TB and/or albumin (Rotterdam criteria).(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP ≤1.67×ULN and TB ≤1 mg/dL.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with no worsening of TB Levels(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with complete biochemical response(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP ≤1.67×ULN, ALP decrease ≥15% and TB ≤ULN.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP <1.5×ULN, ALP decrease ≥15% and TB ≤ULN.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants with ALP ≤ULN and TB ≤ULN.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in PBC risk scores based in Global PBC Study Group (GLOBE) score(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in PBC risk scores based on United Kingdom (UK)-PBC score.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Response based on the normalisation of bilirubin.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Response based on the normalisation of albumin Levels.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in hepatobiliary injury and liver function(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in lipid parameters(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in liver stiffness measurement (LSM)(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in pruritus(At Week 26, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Proportion of responders in PBC Worst Itch NRS according to clinically meaningful change from baseline(At Week 26 and at Week 52 and every 26 weeks until the end of study (up to 6 years))
- Proportion of participants with no worsening of pruritus from baseline(At Week 26 and at Week 52 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in 5D-Itch scale(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a scores(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in Epworth Sleepiness Scale (ESS).(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in PBC-40.(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in EuroQol 5-dimensional 5-level questionnaire (EQ-5D-5L)(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in Patient Global Impression of Severity (PGI-S)(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Patient Global Impression of Change (PGI-C)(At Week 4, Week 13, Week 26, Week 39, and Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)])
- Time to the first occurrence of each of individual adjudicated clinical outcome events(At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years))
- Percentage of participants who experience Treatment Emergent Adverse Events (TEAEs), treatment related TEAEs, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs).(From baseline to end of study (up to 6 years))
- Percentage of participants who develop clinically significant changes from baseline in physical examination findings(From baseline to end of study (up to 6 years))
- Percentage of participants who develop clinically significant changes from baseline in vital signs(From baseline to end of study (up to 6 years))
- Percentage of participants with clinically significant changes in laboratory parameters (blood chemistry, hematology, liver tests, renal tests (including urinalysis).(From baseline to end of study (up to 6 years))
- Percentage of participants who develop clinically significant changes from baseline in ECG readings(From baseline to end of study (up to 6 years))
- Change from baseline in fasting plasma glucose (FPG) Levels(At Week 52 and every 26 weeks until the end of study (up to 6 years))
- Change from baseline in serum markers of bone turnover and in bone mineral density (hip and lumbar)(At Week 52 and every 26 weeks until the end of study (up to 6 years))
- Area under the plasma concentration-time curve from time 0 to 24 hours: AUC0-24(At Week 4)
- Maximum (peak) plasma drug concentration: Cmax(At Week 4)
- Time to reach maximum (peak) plasma concentration following drug administration): Tmax(At Week 4)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)Pneumococcal DiseaseNCT04633226Merck Sharp & Dohme LLC58
已完成
3 期
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)Hereditary Angioedema (HAE)NCT02865720Shire8
已完成
早期 1 期
A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemiaBeta-ThalassemiaNCT06024876CorrectSequence Therapeutics Co., Ltd5
Enrolling By Invitation
1 期
CS-101 in Patients With β-thalassemiaBeta-ThalassemiaNCT06328764CorrectSequence Therapeutics Co., Ltd10
Unknown
早期 1 期
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT04156269iCell Gene Therapeutics12